Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of USD 253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 32 tables and 58 figures, this 121-page report Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cephalosporin

Penicillin

Macrolides

Fluoroquinolones

Quinolones

Monobactam

Aminoglycosides

Carbapenem

Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cell Wall Synthesis Inhibitors

Mycolic Acid Inhibitors

RNA Synthesis Inhibitors

DNA Synthesis Inhibitors

Protein Synthesis Inhibitors

Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Natural Antibiotics

Semi-synthetic Antibiotics

Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Broad-spectrum Antibiotics

Narrow-spectrum Antibiotics

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oral Administration

Intravenous Administration

Other Administration Routes

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Brand Antibiotics

Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 21

2.2 Major Growth Drivers 23

2.3 Market Restraints and Challenges 27

2.4 Emerging Opportunities and Market Trends 30

2.5 Porter's Fiver Forces Analysis 34

3 Segmentation of Asia Pacific Market by Drug Class 38

3.1 Market Overview by Drug Class 38

3.2 Cephalosporin 40

3.3 Penicillin 41

3.4 Macrolides 42

3.5 Fluoroquinolones 43

3.6 Quinolones 44

3.7 Monobactam 45

3.8 Aminoglycosides 46

3.9 Carbapenem 47

3.10 Other Drug Classes 48

4 Segmentation of Asia Pacific Market by Action Mechanism 49

4.1 Market Overview by Action Mechanism 49

4.2 Cell Wall Synthesis Inhibitors 51

4.3 Mycolic Acid Inhibitors 52

4.4 RNA Synthesis Inhibitors 53

4.5 DNA Synthesis Inhibitors 54

4.6 Protein Synthesis Inhibitors 55

4.7 Other Mechanisms 56

5 Segmentation of Asia Pacific Market by Drug Origin 57

5.1 Market Overview by Drug Origin 57

5.2 Natural Antibiotics 59

5.3 Semi-synthetic Antibiotics 60

5.4 Synthetic Antibiotics 61

6 Segmentation of Asia Pacific Market by Activity Spectrum 62

6.1 Market Overview by Activity Spectrum 62

6.2 Broad-spectrum Antibiotics 64

6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of Asia Pacific Market by Route of Administration 66

7.1 Market Overview by Route of Administration 66

7.2 Oral Administration 68

7.3 Intravenous Administration 69

7.4 Other Administration Routes 70

8 Segmentation of Asia Pacific Market by Drug Type 71

8.1 Market Overview by Drug Type 71

8.2 Brand Antibiotics 73

8.3 Generic Antibiotics 74

9 Asia-Pacific Market 2019-2030 by Country 75

9.1 Overview of Asia-Pacific Market 75

9.2 Japan 78

9.3 China 81

9.4 Australia 83

9.5 India 85

9.6 South Korea 87

9.7 Rest of APAC Region 89

10 Competitive Landscape 91

10.1 Overview of Key Vendors 91

10.2 New Product Launch, Partnership, Investment, and M&A 94

10.3 Company Profiles 95

Abbott Laboratories 95

Astellas Pharma 97

AstraZeneca Plc 98

Bayer AG 99

Bristol Myers Squibb Company 100

Cipla Inc. 101

Dr. Reddy's Laboratories Ltd. 102

Eli Lilly and Company 103

F. Hoffmann-La Roche Ltd. 104

Gilead Sciences, Inc. 105

GlaxoSmithKline plc. 106

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 107

Mayne Pharma Group Ltd. 108

MELINTA THERAPEUTICS, INC. 109

Merck KGaA 110

Novartis AG 111

Pfizer Inc. 112

Sanofi 113

Sun Pharmaceutical Industries Ltd. 114

11 Investing in Asia Pacific Market: Risk Assessment and Management 115

11.1 Risk Evaluation of Asia Pacific Market 115

11.2 Critical Success Factors (CSFs) 118

Related Reports and Products 121


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. Asia Pacific Antibiotics Market, 2019-2030, USD mn 20

Figure 6. Impact of COVID-19 on Business 21

Figure 7. Primary Drivers and Impact Factors of Asia Pacific Antibiotics Market 23

Figure 8. GDP per capita in the World, 1960-2018, USD thousand 26

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26

Figure 10. Primary Restraints and Impact Factors of Asia Pacific Antibiotics Market 27

Figure 11. Investment Opportunity Analysis 31

Figure 12. Porter's Fiver Forces Analysis of Asia Pacific Antibiotics Market 34

Figure 13. Breakdown of Asia Pacific Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39

Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value (USD mn) and Share (%) 39

Figure 15. Asia Pacific Antibiotics Market: Cephalosporin, 2019-2030, USD mn 40

Figure 16. Asia Pacific Antibiotics Market: Penicillin, 2019-2030, USD mn 41

Figure 17. Asia Pacific Antibiotics Market: Macrolides, 2019-2030, USD mn 42

Figure 18. Asia Pacific Antibiotics Market: Fluoroquinolones, 2019-2030, USD mn 43

Figure 19. Asia Pacific Antibiotics Market: Quinolones, 2019-2030, USD mn 44

Figure 20. Asia Pacific Antibiotics Market: Monobactam, 2019-2030, USD mn 45

Figure 21. Asia Pacific Antibiotics Market: Aminoglycosides, 2019-2030, USD mn 46

Figure 22. Asia Pacific Antibiotics Market: Carbapenem, 2019-2030, USD mn 47

Figure 23. Asia Pacific Antibiotics Market: Other Drug Classes, 2019-2030, USD mn 48

Figure 24. Breakdown of Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50

Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value (USD mn) and Share (%) 50

Figure 26. Asia Pacific Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, USD mn 51

Figure 27. Asia Pacific Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, USD mn 52

Figure 28. Asia Pacific Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, USD mn 53

Figure 29. Asia Pacific Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, USD mn 54

Figure 30. Asia Pacific Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, USD mn 55

Figure 31. Asia Pacific Antibiotics Market: Other Mechanisms, 2019-2030, USD mn 56

Figure 32. Breakdown of Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58

Figure 33. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value (USD mn) and Share (%) 58

Figure 34. Asia Pacific Antibiotics Market: Natural Antibiotics, 2019-2030, USD mn 59

Figure 35. Asia Pacific Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, USD mn 60

Figure 36. Asia Pacific Antibiotics Market: Synthetic Antibiotics, 2019-2030, USD mn 61

Figure 37. Breakdown of Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63

Figure 38. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value (USD mn) and Share (%) 63

Figure 39. Asia Pacific Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, USD mn 64

Figure 40. Asia Pacific Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, USD mn 65

Figure 41. Breakdown of Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67

Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Route of Administration, Value (USD mn) and Share (%) 67

Figure 43. Asia Pacific Antibiotics Market: Oral Administration, 2019-2030, USD mn 68

Figure 44. Asia Pacific Antibiotics Market: Intravenous Administration, 2019-2030, USD mn 69

Figure 45. Asia Pacific Antibiotics Market: Other Administration Routes, 2019-2030, USD mn 70

Figure 46. Breakdown of Asia Pacific Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71

Figure 47. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value (USD bn) and Share (%) 72

Figure 48. Asia Pacific Antibiotics Market: Brand Antibiotics, 2019-2030, USD bn 73

Figure 49. Asia Pacific Antibiotics Market: Generic Antibiotics, 2019-2030, USD bn 74

Figure 50. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue 76

Figure 51. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value (USD bn) and Share (%) 77

Figure 52. Antibiotics Market in Japan, 2019-2030, USD bn 79

Figure 53. Antibiotics Market in China, 2019-2030, USD bn 81

Figure 54. Antibiotics Market in Australia, 2019-2030, USD bn 83

Figure 55. Antibiotics Market in India, 2019-2030, USD bn 85

Figure 56. Antibiotics Market in South Korea, 2019-2030, USD bn 87

Figure 57. Antibiotics Market in Rest of APAC, 2019-2030, USD bn 89

Figure 58. Growth Stage of Asia Pacific Antibiotics Industry over the Forecast Period 91


List of Table

Table 1. Snapshot of Asia Pacific Antibiotics Market, 2019-2030 18

Table 2. Main Product Trends and Market Opportunities in Asia Pacific Antibiotics Market 30

Table 3. Asia Pacific Antibiotics Market by Drug Class, 2019-2030, USD mn 38

Table 4. Asia Pacific Antibiotics Market by Action Mechanism, 2019-2030, USD mn 49

Table 5. Asia Pacific Antibiotics Market by Drug Origin, 2019-2030, USD mn 57

Table 6. Asia Pacific Antibiotics Market by Activity Spectrum, 2019-2030, USD mn 62

Table 7. Asia Pacific Antibiotics Market by Route of Administration, 2019-2030, USD mn 66

Table 8. Asia Pacific Antibiotics Market by Drug Type, 2019-2030, USD bn 71

Table 9. APAC Antibiotics Market by Country, 2019-2030, USD bn 76

Table 10. Japan Antibiotics Market by Drug Class, 2019-2030, USD mn 80

Table 11. Japan Antibiotics Market by Drug Origin, 2019-2030, USD mn 80

Table 12. Japan Antibiotics Market by Route of Administration, 2019-2030, USD mn 80

Table 13. China Antibiotics Market by Drug Class, 2019-2030, USD mn 82

Table 14. China Antibiotics Market by Drug Origin, 2019-2030, USD mn 82

Table 15. China Antibiotics Market by Route of Administration, 2019-2030, USD mn 82

Table 16. Australia Antibiotics Market by Drug Class, 2019-2030, USD mn 84

Table 17. Australia Antibiotics Market by Drug Origin, 2019-2030, USD mn 84

Table 18. Australia Antibiotics Market by Route of Administration, 2019-2030, USD mn 84

Table 19. India Antibiotics Market by Drug Class, 2019-2030, USD mn 86

Table 20. India Antibiotics Market by Drug Origin, 2019-2030, USD mn 86

Table 21. India Antibiotics Market by Route of Administration, 2019-2030, USD mn 86

Table 22. South Korea Antibiotics Market by Drug Class, 2019-2030, USD mn 88

Table 23. South Korea Antibiotics Market by Drug Origin, 2019-2030, USD mn 88

Table 24. South Korea Antibiotics Market by Route of Administration, 2019-2030, USD mn 88

Table 25. Antibiotics Market in Rest of APAC by Country, 2019-2030, USD bn 90

Table 26. Abbott Laboratories: Company Snapshot 95

Table 27. Abbott Laboratories: Business Segmentation 95

Table 28. Abbott Laboratories: Product Portfolio 96

Table 29. Abbott Laboratories: Revenue, 2016-2018, USD mn 96

Table 30. Abbott Laboratories: Recent Developments 96

Table 31. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 116

Table 32. Critical Success Factors and Key Takeaways 119

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us